5 assets in Childhood Myelodysplastic Syndrome

Therapeutic assets addressing Childhood Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Childhood Myelodysplastic Syndrome	Children's Oncology Group	P3	BBB (73)
Cytarabine Childhood Myelodysplastic Syndrome	Children's Oncology Group	P3	BBB (72)
Methotrexate Childhood Myelodysplastic Syndrome	Children's Oncology Group	P3	BB (67)
Hydrocortisone Childhood Myelodysplastic Syndrome	Children's Oncology Group	P3	BB (64)
Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) Childhood Myelodysplastic Syndrome	Children's Oncology Group	P1	CC (43)